Simplified Chinese

English

Home page

A “nemesis” of pneumonia: Minhai Biologics’ 23-valent pneumococcal vaccine has been successfully launched.

Release date:

2019-08-22

Author:

Source:

Abstract

On August 13, 2019, the 23-valent pneumococcal polysaccharide vaccine manufactured by Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Biotechnology) successfully passed the review of the National Medical Products Administration and obtained the batch release certificate for biological products. Following procedures such as inclusion in provincial-level vaccine procurement platforms, the product has been progressively distributed to local markets. With an annual production capacity of 10 million doses, Minhai Biotechnology’s 23-valent pneumococcal polysaccharide vaccine is currently the only one available in two dosage forms. It is indicated for the prevention of diseases—including pneumonia, meningitis, otitis media, and bacteremia—caused by 23 serotypes of Streptococcus pneumoniae, and is suitable for individuals aged 2 years and older who are at increased risk.

　　Minhai Biologics’ 23-valent pneumococcal polysaccharide vaccine has an annual production capacity of 10 million doses and is currently the only 23-valent pneumococcal polysaccharide vaccine available in two dosage forms, indicated for… It prevents diseases such as pneumonia, meningitis, otitis media, and bacteremia caused by 23 pneumococcal serotypes, and is indicated for susceptible individuals aged 2 years and older, particularly the elderly, individuals with normal immune function but chronic illnesses, those with compromised immunity, asymptomatic and symptomatic HIV-infected persons, patients with cerebrospinal fluid leakage, and high‑risk populations—including residents or workers in settings where exposure to pneumococcus or its complications is frequent.

　　Currently, the pneumococcal vaccines available in the domestic market fall into two main categories: the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine. Among these, the 13-valent pneumococcal conjugate vaccine is primarily intended for immunization of infants and young children under the age of two.

　　The Chinese Society of Preventive Medicine states in its “Technical Guidelines for the Use of Vaccines Against Streptococcus pneumoniae–Related Diseases” that: “Streptococcus pneumoniae is a major pathogen responsible for morbidity and mortality among children and the elderly in China. Vaccination is an essential measure for the prevention of pneumococcal disease.”

　　The 23-valent pneumococcal polysaccharide vaccine, Weiminfeile, manufactured by Minhai Biotechnology, has now received batch release certification, marking its official entry into the market and providing a protective option for eligible recipients.

Keywords:

Minhai Biotechnology was named to the 2019 Top 100 List of Technological Innovation among Beijing Private Enterprises.

Phoenix TV visited Kangtai Biological, shedding light on how vaccines safeguard the public safety baseline.

Recommended Reading

Batch Release Status of the Company’s Products in 2026

The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.

Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.

Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09

Online Customer Service

Telephone

400 189 9806

Contact Information

Customer Service Hotline

4001899806

Phone number

010-59613600

Official Website

http://www.biominhai.com

Company Address

No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing

WeChat Official Account

Business license

Website Development: China Enterprise Dynamics

Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.